AbCellera Biologics Inc. (ABCL) Return on equity 2019–2025
AbCellera Biologics Inc. (ABCL) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-15.1%FY2025 · since FY2019: -21.6% → -15.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -15.1% | +0.3 pp |
| FY2024 | -15.4% | -2.7 pp |
| FY2023 | -12.7% | -25.6 pp |
| FY2022 | 12.9% | -2.1 pp |
| FY2021 | 15.0% | +0.6 pp |
| FY2020 | 14.3% | +35.9 pp |
| FY2019 | -21.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice